Agent PFS OS QOL ORR
1.Angiogenesis inhibitors 1a.Antibodies, peptides Bevacizumab Adjuvant  setting Burger [12] 14.1 vs 11.2 vs 10.3 mos, HR 0.717, p<0.0001 No difference Lower in bev arm during chemo  
Oza[13] 20.3 vs 21.8 mos HR 0.81 95%CI 0.70-0.94, p=0.0041 No difference    
Recurrent – Platinum sensitive Aghajanian[15] 12.4 vs 8.4 mos, HR 0.484 95%CI 0.388-0.605, P<0.0001 No difference   78.5% vs 57.4% p<0.0001
Recurrent – Platinum resistant Pujade-Lauraine[16] 6.7 vs 3.4 mos HR 0.48 95%CI 0,38-0.60, p<0.001 No difference    
Trebananib Monk [28] 7.2 vs 5.4 mos HR 0.66 95%CI 0.57-0.77, p<0.001 No difference    
1b.Small Molecule inhibitors Targeting VEGFR and c-kit Cediranib Recurrent -Platinum sensitive Ledermann[35] 12.6 vs 9.4 mos, HR 0.57 95%CI 0.45-0.74, p=0.00001 20.6 vs 17.6 mos HR 0.70p=0.419    
Nintedanib Baumann [37] 17.3 vs 16.6 mos, HR 0.84, 95% CI 0.72-0.98, p=0.0239 No difference    
Targeting VEGFR, PDGFR, c-kit Pazopanib Adjuvant Du Bois [43] 17.9 vs 12.3 mos, HR 0.766, 95%CI 0.64-0.91, p=0.0021      
2. EGF Inhibitors 2a. Antibodies Pertuzumab       14% vs 5%
3. Targeting folate receptor alpha Farletuzumab Recurrent – Platinum resistant Walters [54] Recurrent – Platinum sensitive Vergote[55] No benefit No benefit      
EC145 Recurrent – Platinum resistant Naumann[57] Pending      
8. Inhibition of DNA repair Olaparib Adjuvant-maintenance Lheueux[76] Recurrent -Platinum sensitive (NCT01874353) Pending Pending      
Niraparib Recurrent – Platinum sensitive (NCT01847274) Pending      
Rucaparib Recurrent – Platinum sensitive (NCT01968213) Pending      
Table 2: Randomized Trials of Targeted Agents in Ovarian Cancer.